3,922 Shares in SPDR S&P Biotech ETF $XBI Acquired by Blue Capital Inc.

Blue Capital Inc. bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,922 shares of the exchange traded fund’s stock, valued at approximately $478,000.

A number of other hedge funds have also bought and sold shares of XBI. Avoro Capital Advisors LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter worth $256,053,000. Wells Fargo & Company MN grew its holdings in shares of SPDR S&P Biotech ETF by 75.7% during the fourth quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock valued at $434,835,000 after buying an additional 1,536,122 shares during the last quarter. OMERS ADMINISTRATION Corp increased its position in shares of SPDR S&P Biotech ETF by 42,425.2% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock valued at $145,147,000 after acquiring an additional 1,187,907 shares during the period. Morgan Stanley increased its position in shares of SPDR S&P Biotech ETF by 8.3% in the 4th quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock valued at $1,401,181,000 after acquiring an additional 882,718 shares during the period. Finally, Assetmark Inc. increased its position in shares of SPDR S&P Biotech ETF by 1,042,265.6% in the 4th quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock valued at $77,528,000 after acquiring an additional 635,782 shares during the period.

SPDR S&P Biotech ETF Price Performance

Shares of XBI stock opened at $140.72 on Friday. The business has a fifty day moving average of $133.36 and a 200 day moving average of $127.61. SPDR S&P Biotech ETF has a 1 year low of $80.90 and a 1 year high of $143.46. The firm has a market capitalization of $8.98 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.